Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status

  title={Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status},
  author={Abid H. Banday and Shameem Ahmad Shameem and Sheikh Ajaz},
  journal={Slas Discovery},
  pages={1097 - 1107}
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019. Since then, the virus has stretched its grip to almost all the countries in the world, affecting millions of people and causing enormous casualties. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2019. As of June 12, 2020, almost 7.30 million people have already been infected globally, with 413,000 reported casualties. In the United States… 

Figures and Tables from this paper

Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic

The ongoing clinical trial landscape of the COVID-19 as well as repurposed vaccines, an insight into the current status of the available antigenic epitopes for SARS-CoV-2 and different types of vaccine platforms of CO VID-19 vaccines has been discussed.

Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease

The current review highlights the different approaches and technologies used around the world for the design and development of the vaccines and also focuses on the recent status of the SARS-CoV-2 vaccine candidates under development by various institutions to combat the world threat of COVID-19 pandemic.



SARS-CoV-2 Vaccines: Status Report

First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

The data from this small-sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients, and suggest that repurposing danobrevir for COVID-19 is a promising therapeutic option.

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections

Compassionate Use of Remdesivir for Patients with Severe Covid-19

In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients, and Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesavir therapy.

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route and work that may provide a basis for development of anticoronaviral drugs.

The mechanism of resistance to favipiravir in influenza

It is demonstrated that a mutation in a conserved region of the viral RNA polymerase confers resistance to favipiravir in vitro and in cell culture, and this mutation has a cost to viral fitness, but fitness can be restored by a compensatory mutation in the polymerase.

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.

Old Drugs for a New Bug

While the World Health Organization stopped tracking SARS cases earlier this summer, the agency warns that the disease may simply be napping and is backing work on anti-SARS drugs.